微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 70.96% | 2.82% | 1.68% | 34/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 69.78% | 0.1% | 1.18% | 33/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 68.97% | -2.1% | -0.81% | 32/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 69.53% | 8.35% | 0.75% | 33/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 69.01% | 8.29% | -1% | 33/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 69.71% | 8.99% | -1.05% | 34/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 70.45% | 8.69% | 9.77% | 30/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 64.18% | -6.21% | 0.7% | 42/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 63.73% | -6.82% | -0.36% | 43/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 63.96% | -8.73% | -1.32% | 45/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 64.82% | -8.64% | -5.27% | 41/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 68.42% | -3.46% | 0.04% | 40/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 68.4% | -5.74% | -2.41% | 40/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 70.08% | -3.14% | -1.22% | 40/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 70.95% | -4.31% | 0.11% | 38/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 70.87% | -4.02% | -2.32% | 42/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 72.56% | 1.08% | 0.29% | 32/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 72.35% | 3.65% | -2.41% | 33/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 74.14% | 11.08% | 0.4% | 25/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 73.85% | 0.99% | 2.87% | 32/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 71.78% | -1.37% | 2.83% | 30/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 69.81% | -2.71% | 4.58% | 34/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 66.75% | -2.54% | -8.72% | 34/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 73.12% | 13.71% | 0.46% | 31/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 72.78% | 16.64% | 1.44% | 23/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 71.75% | 16.06% | 4.76% | 26/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 68.49% | 17.02% | 6.51% | 24/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 64.3% | 23.39% | 3.05% | 43/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 62.4% | 22.69% | 0.94% | 37/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 61.82% | 25.28% | 5.63% | 40/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 58.53% | 27.3% | 12.31% | 39/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 52.11% | 1.97% | 2.46% | 59/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 50.86% | 2% | 3.07% | 45/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 49.34% | -9.4% | 7.33% | 47/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 45.98% | 2% | -10.04% | 43/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 51.11% | -3.78% | -6.16% | 48/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 54.46% | 14.01% | 2.53% | 29/159 | 45.89% | 贝达药业 | 95.89% | 行业排名> |
| 2015-12-31 | 53.12% | 3.63% | 3.63% | 35/159 | 45.97% | 微芯生物 | 97.46% | 行业排名> |